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Abstract
Fibroblast growth factors (FGFs) regulate several cellular developmental processes by interacting 
with cell surface heparan proteoglycans and transmembrane cell surface receptors (FGFR). The 
interaction of FGF with heparan sulfate (HS) is known to induce protein oligomerization, increase 
the affinity of FGF towards its receptor FGFR, promoting the formation of the HS–FGF–FGFR 
signaling complex. Although the role of HS in the signaling pathways is well recognized, the 
details of FGF oligomerization and formation of the ternary signaling complex are still not clear, 
with several conflicting models proposed in literature. Here, we examine the effect of size and 
sulfation pattern of HS upon FGF1 oligomerization, binding stoichiometry and conformational 
stability, through a combination of ion mobility (IM) and theoretical modeling approaches. Ion 
mobility-mass spectrometry (IMMS) of FGF1 in the presence of several HS fragments ranging 
from tetrasaccharide (dp4) to dodecasaccharide (dp12) in length was performed. A comparison of 
the binding stoichiometry of variably sulfated dp4 HS to FGF1 confirmed the significance of the 
previously known high-affinity binding motif in FGF1 dimerization, and demonstrated that certain 
tetrasaccharide-length fragments are also capable of inducing dimerization of FGF1. The degree of 
oligomerization was found to increase in the presence of dp12 HS, and a general lack of specificity 
for longer HS was observed. Additionally, collision cross-sections (CCSs) of several FGF1–HS 
complexes were calculated, and were found to be in close agreement with experimental results. 
Based on the (CCSs) a number of plausible binding modes of 2:1 and 3:1 FGF1–HS are proposed.
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Introduction
Fibroblast growth factors (FGFs) are mitogenic polypeptide growth factors expressed in all 
multicellular organisms [1]. Eighteen human FGFs have been identified so far, which share 
13%–71% sequence similarity and a homology core domain that consists of three copies of a 
basic four-stranded antiparallel beta sheet. These FGFs differ in their size, their interaction 
with receptors, and their biological functions [2, 3]. FGFs are potent mitogens and mediate a 
multitude of biological processes, including cell proliferation, cell differentiation, cell 
migration, morphogenesis, and angiogenesis [4]. Aberrant FGF signaling promotes tumor 
development and tumor resistance to anti-angiogenic and other chemotherapies by directly 
driving cancer cell proliferation and survival [5]. FGF1 (along with FGF2) were the first 
FGFs to be identified and extensively studied [6].
The growth stimulatory activity of FGFs is achieved through direct interaction with two 
types of receptors on the cell surface [7]. The high affinity receptor FGFR are 
transmembrane proteins, four isoforms of which have been identified in mammals. Three 
extracellular immunoglobulin (Ig)-like domains and an intracellular cytoplasmic tyrosine 
kinase domain are linked though a single transmembrane helix to form the structure of 
FGFRs [8]. The ligand binding activity and specificity of FGFRs manifest through the Ig-
domains II and III and the linker connecting the two domains [9]. Alternative splicing in Ig 
domain III dramatically alters the affinity of the FGFRs for FGFs and introduces the first 
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level of specificity in FGF signaling for all FGF ligands except for FGF1, which serves as a 
universal ligand and activates all of the FGFRs [10].
The low affinity receptor heparan sulfates (HS) are linear sulfated glycosaminoglycan 
(GAG) polysaccharides comprising of alternating N-acetyl glucosamine and uronic acid 
disaccharide units linked through a 1–4 glycosidic linkage. HS are abundant components 
found on cell surfaces, for example, syndecans and glypicans, or in the extracellular matrix, 
such as perlecan, agrin, or collagen XVIII [11]. The structural polydispersity and 
heterogeneity of HS is a result of incomplete enzymatic modifications of HS in Golgi 
apparatus, including: (1) replacing N-acetyl with N-sulfation of glucosamine by N-
deacetylase/N-sulfotranferases (NDSTs), (2) epimerization of glucuronic acid to iduronic 
acid by C5-epimerase, (3) addition of sulfo group to the 2-O position of iduronic acid by 2-
O sulfotransferase, (4) addition of sulfo group to the 6-O and, rarely, the 3-O positions of 
glucosamine by 6-O and 3-O sulfotranferases [12]. These non-template enzymatic 
modifications produce domains that are either highly N-sulfated, highly N-acetylated, or 
mixed domains of HS, which serve as potential binding site for a large array of HS binding 
proteins [13].
It has been generally appreciated that HS plays an essential role in transmitting extracellular 
signals to intracellular signaling pathways through direct interactions with both FGF and 
FGFR [14]. The binding of FGF to HS induces FGF oligomerization, increases the affinity 
of FGF to the extracellular part of FGFR, and further enables activation of FGFR and the 
formation of the highly stable HS–FGF–FGFR trimeric signaling complex [15]. The kinase 
domains from activated FGFRs are activated through transphosphorylation, followed by 
recruiting adapter protein to the activated receptors and triggering the downstream 
intracellular signaling cascades [16].
Although the role of HS in FGF signaling has been well elucidated, the structural details of 
how the FGFs oligomerize in the presence of HS, and how the trimeric signaling complex of 
FGF, FGFR, and HS are integrated is still a matter of debate. Two physiologically relevant 
FGF dimerization configurations with HS have been proposed [17]: The trans-oriented form 
features two FGF molecules arranged on opposite sides of one HS domain, and is 
characterized by a complete absence of FGF–FGF interactions. The cis-oriented form 
features two FGF molecules present on the same side of the HS domain, requiring a HS with 
sufficient length. Many studies suggest that FGF1 favors the formation of trans form dimeric 
complex, and so far the crystallographic structure of only the trans form has been observed 
for FGF1 [18]. In contrast, for FGF2, a cis and a trans dimeric form may coexist [19]. In the 
presence of FGFR, two crystallographic ternary complex structures have been resolved, the 
2:2:1 FGF1–FGFR2–HS dodecasaccharide model (or Pellegrini model [20]) and the 2:2:2 
FGF2–FGFR1–HS dodecasaccharide model (or Schlessinger model [21]), differing in their 
preparation, binding stoichiometry, intermolecular interactions, as well as the protein species 
used.
It has been long disputed whether FGF1 recognizes a consensus sequence with a specific 
sulfation pattern and minimum length, similar to the specific pentasaccharide sequences 
recognized by Antithrombin III (ATIII) [22]. HS octasaccharide and decasaccharide have 
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been suggested to be the minimum length required for signaling [23], and a trisaccharide HS 
motif of IdoA2S-α-(1-4)-GlcNS6S-α-(1-4)-IdoA2S on HS oligosaccharides has been 
recognized to show strong binding affinity for FGF1 [24], but the minimum length of HS 
required to activate FGF signaling is still uncertain. There is considerable inconsistency in 
the literature about the binding specificity of FGF1–HS interaction, where some results 
suggest that an overall degree of sulfation rather than a distinct sulfation pattern mediates 
this interactions [25, 26], whereas others propose binding selectivity that is highly 
susceptible to subtle changes to the fine structure of HS regarding the particular location of 
sulfation [27–30]. Studies of the binding sequence for FGFs show that they each have 
different preferences for the sulfation pattern of HS [29]. Additionally, some other studies 
indicate that specific FGF-FGFR pairs, rather than FGF itself, dictate binding specificity and 
affinity [31]. For example, HS deficient in 2-O- and 6-O- sulfation still maintains its 
activating effect on FGF1-FGFR2 signaling but not FGF1-FGFR1 or FGF7-FGFR2b 
signaling [32].
A wide array of biophysical techniques, including X-ray crystallography [18], NMR [33], 
size exclusion chromatography [34], size exclusion chromatography followed by 
hydrophobic trapping [35], isothermal calorimetry [36], surface plasmon resonance [37], and 
affinity co-electrophoresis [38], have been applied to elucidate the nature of these molecular 
interactions. Recently, ion mobility-mass spectrometry (IMMS), a gas-phased biophysical 
technique that separates biomolecules based on their mobilities has emerged and found 
numerous applications such as measuring conformational change in proteins upon ligand-
binding [39], determining binding affinity and specificity [40], monitoring real-time 
conformational dynamics [41], detecting intermediate structures [42], and elucidating the 
architecture of protein assemblies [43]. Furthermore, with the commercialization of Synapt 
instruments from Waters Corporation, traveling wave ion mobility spectrometry (TWIMS) 
has become a widely used approach for the study of biomolecular structure and dynamics 
[44]. IMMS studies are often supported by molecular modeling studies, which provide 
computational predictions of molecular structure, binding orientations, binding affinities, as 
well as theoretical estimation of the molecular shape collision cross-sections (CCSs), and 
serve a critical role for the correct interpretation of experimental findings.
We recently applied TWIMS to examine the well-characterized, highly specific interaction 
between ATIII and a synthetic heparin (Hp) pentasaccharide [40]. We successfully measured 
and theoretically validated the conformational change within ATIII induced by the binding 
of Hp while maintaining the solution structure of ATIII and its complexes as well as the 
binding selectivity and specificity of Hp–ATIII interaction. In this study, we extended this 
method to a more complicated system of FGF1 signaling, in order to investigate the 
conformational and stoichiometric details of the binding of FGF1 and HS. TWIMS 
experiments and molecular modeling techniques were combined in order to address the 
minimum length of HS required to induce FGF1 dimerization, the binding stoichiometry for 
the interaction of FGF1 and HS of varying sizes and sulfation patterns, the selectivity of the 
interaction between FGF1 and HS, and the conformational stability of FGF1 and its HS 
bound complexes. This work provides more details to the model of the manner in which HS 
interacts with FGF1, as well as additional validation for the approach of using gas-phase 
measurements of GAG–protein interactions to derive biologically relevant structural details.
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Experimental
Reagents
All chemicals and solvents (ammonium acetate, methanol, water, and formic acid) were of 
HPLC grade and purchased from Sigma-Alldrich, (St. Louis, MO). Human recombinant 
FGF 1 expressed in Escherichia coli was a gift from Amgen (Thousand Oaks, CA, USA). 
Protein calibrants (myoglobin from equine heart, cytochrome c from equine heart, avidin 
from egg white, concanavalin A from Canavalia ensiformis, and bovine serum albumin) 
were purchased from Sigma-Aldrich. HS dodecasaccharides were chemo-enzymatically 
synthesized as previously described [45]. HS tetrasaccharides were synthesized as 
previously described based by fluorous supported modular synthesis [46].
Sample Preparation
For MS analyses under nondenaturing conditions, FGF1 was diluted in 20 mM ammonium 
acetate buffer, pH 6.8, to a final concentration of 10 μM. FGF1–HS complex was obtained 
by incubating FGF1 with HS oligosaccharides at room temperature for 60 min. Protein 
calibrants were diluted in either denaturing solution or nondenaturing solution to a final 
concentration of 10 μM.
IMMS Measurement and Data Analysis
NanoESI-IMMS experiments were performed using a quadrupole-TWIMS-TOF hybrid 
mass spectrometer (Synapt G2 HDMS; Waters Corp., Manchester, UK) in positive 
ionization mode. Protein samples were injected into the nanoESI source through a fused-
silica emitter (PicoTip; New Objective, Woburn, MA, USA) with a flow rate varying from 
0.2 to 0.5 uL/min. Experimental parameters were carefully tuned to prevent the protein and 
protein complex from unfolding or losing integrity due to extensive activation, while 
keeping substantial ion transmission, including controlling the collisional energy in the ion 
guides and keeping the source temperature and desolvation energy low. The applied 
experimental parameters were capillary voltage, 1.4 kV; sampling cone voltage, 20 V; 
extraction cone voltage, 5 V; source temperature, 30 °C; flow rate of nitrogen in the IM ion 
guide, 50 mL/min; flow rate of helium in the helium cell, 180 mL/ min; transfer collision 
energy, 0 V. Different sets of wave height and corresponding wave velocity were examined 
to optimize the mobility separation. The drift times of the calibrants and FGF1 samples were 
measured and identical experimental conditions were stringently applied.
For monitoring the collisional induced unfolding (CIU) of FGF1 and FGF1–HS complexes, 
protein ions of a selected charge state were isolated in a quadrupole mass filter and activated 
in the trap ion guide where subsequent collisional induced activation of ions takes place, 
followed by separation in the TWIMS ion mobility stage, and detection by TOF-MS.
Data analysis was performed using MassLynx 4.1 and Driftscope (Waters Corp., 
Manchester, UK). The CIU data was analyzed using CIUSuite [47]. CIU fingerprints of 
protein ions, which records the relative ion intensity (normalized and smoothed using 
Savitsky-Golay filter) as a function of collision energy and drift times, were shown in a 2-D 
contour plot using the CIUSuite plot function. The CIUsuite detect function was applied to 
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identify and extract the most intense CIU features of the fingerprint based on a first 
derivative analysis, providing centroid drift times, transitional voltage, and stability range of 
each detected feature.
Converting Drift Times into CCSs
The CCS measurements were calibrated based on an empirical relationship between the drift 
times of protein calibrants and their known CCS obtained previously by DTIMS [48]. 
Briefly, a selected set of native and denatured protein calibrants, with a mass range from 12 
to 102 KDa and a CCS range from 2303 to 5550 Å2 were employed. The drift times of these 
calibrates were corrected for mass-dependent flight time spent in the transfer ion guide and 
TOF mass analyzer and mass-independent flight time spent in the transfer ion guide. The 
CCSs of calibrants were corrected for their charge state and reduced mass with respect to the 
buffer gas. The natural logarithm of corrected CCSs were plotted against the natural 
logarithm of corrected drift times and a mathematical formula (LnΩ′ = A × Lndt′ + B) was 
derived. The calibration coefficient A was extracted to calculate the effective drift times dt″: 
. A calibration curve was generated by plotting the literature CCSs as a 
function of dt″. The experimental CCS of the analyte ion can be derived from this 
calibration curve based on the measured drift time [49, 50].
Preparation of Theoretical Models
FGF1–dp4 Complex—The Protein Data Bank (PDB) contains several models of wild-
type human FGF1 in complex with heparin oligosaccharide, and each of them displays 
slightly differing contacts with the protein. The interaction energy between each protein–HS 
tetrasaccharide complex was calculated using a short minimization in implicit solvent 
followed by single frame binding free energy calculation to select one model for further 
theoretical investigation (see details in Supplementary Data and Supplementary Table 1). 
The complex that shows the strongest interaction (2AXM chain B) [18] was used for all 
further calculations.
FGF1–HS Complexes for d6, dp8, dp10, and dp12—2AXM chain B bound to Hp 
hexasaccharide was used to build the model for 1:1 and 2:1 FGF1–HS hexasaccharide 
complex. In order to avoid disrupting the contacts that the hexasaccharide made with the two 
FGF1 molecules, the heparin sequence from the crystal structure was kept, which is different 
from the experimentally used dp6 fragment.
The chosen dp4 complex was used and the heparin sequence was extended on either side 
using tleap to build the FGF1–dp8 complexes. The FGF1–dp6 complex was used and 
additional residues were added on either side of the existing dp6, according to the 
experimentally used sequences (Table 1), using tleap to build the FGF1–dp10 and the 
FGF1–dp12 complexes.
2:1 FGF1–dp12 cis Model and 3:1 FGF–HS–dp12 Model—Two models were built 
for the 2:1 FGF1-fully sulfated dp12 in the cis conformation. Cis-model-1 was modeled 
using two FGF1–dp6 molecules connected through the GAG chain using tleap. First chain D 
Zhao et al. Page 6
J Am Soc Mass Spectrom. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of the crystal structure of apo-FGF1 dimer (PDB id: 2AFG [51]) was superimposed on chain 
A of FGF1– dp6 crystal structure (PDB id: 2AXM) and the coordinates for the dp6 were 
transferred to make 2AFG–dp6 complex to build the second 2:1 cis complex (Cis-model-2). 
This dp6 structure was extended to match the experimentally used fully sulfated dp12 by 
adding three residues on either side, using tleap.
3:1 FGF1 A fully sulfated dp12 complex—was built by connecting the available 
crystal structure for 2:1 FGF1–dp6 dimeric complex with a 1:1 FGF1–dp6 monomeric 
complex through the HS chain.
Molecular Dynamics Simulations
Topology and coordinate files for each system were generated using the tleap program, 
employing the ff99SB [52] and GLYCAM06 (version j) [53, 54] parameters for the protein 
and GAGs, respectively. Each system underwent energy minimization (1000 steps) in 
implicit solvent (IGB = 2). The net charge on each system, after energy minimization, was 
neutralized by addition of an appropriate number of counter ions (Na+ or Cl−). This was 
followed by solvation with TIP3P [55] water molecules in a cubic box extending at least 12 
Å from any atom of the solute.
All MD simulations were performed with the GPU implementation of pmemd, 
pmemd.cuda_SPDP [56] in Amber14 [57]. Energy minimization of the solvent was 
performed in an NVT ensemble (1000 steps of steepest descent, 24,000 steps of conjugate 
gradient), followed by a full system energy minimization (1000 steps of steepest descent, 
24,000 steps of conjugate gradient). The systems were heated from 5 to 300 K over 60 ps in 
an NVT ensemble, with a weak positional restraint (10 kcal/mol-Å2) on the atoms in the 
solute. A Berendsen-type thermostat [58] with a time coupling constant of 1 ps was utilized 
for temperature regulation. Equilibration and production were performed at constant 
pressure (NPT ensemble; 1 atm) with a pressure relaxation time of 1 ps. After the heating 
step, the restraints were removed from the solute atoms, and the entire system was allowed 
to equilibrate at 300 K for 1 ns. All covalent bonds involving hydrogen atoms were 
constrained using the SHAKE [59] algorithm, allowing a simulation time step of 2 fs. 
Scaling factors for 1–4 interactions were set to the recommended values of 1.0 and 1.2 for 
the GAG [53] and protein [52], respectively, and a non-bonded interaction cutoff of 8.0 Å 
was employed. Long-range electrostatics were computed with the particle mesh Ewald 
(PME) method. Data were collected for 200 ns for each system. Post-processing of the MD 
simulations was performed using CPPTRAJ [60] module of Amber. The graphical 
representations were generated using VMD [61].
Binding Energy Calculations
Models of the gas-phase complexes were generated from the MD simulations by removing 
the water molecules and subjecting the biomolecules to in vacuo minimization (IMIN = 5) 
with the SANDER module of AMBER14. This was performed for 5000 frames selected at 
even steps from the last 100 ns of the solvated simulation, and the resultant gas-phase 
trajectory was used to calculate the binding free energy in the gas phase using the 
MMPBSA.py script [62].
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CCS Calculations
CCSs were calculated using 50 frames from the last 100 ns of the simulation using 
MOBCAL [63]. Each of these frames was minimized in vacuo, followed by the calculation 
of CCS using the projection approximation and trajectory methods.
Results and Discussion
IMMS of Unbound FGF1 and HS Tetrasaccharide-Bound FGF1
Under nondenaturing conditions, in the absence of HS, FGF1 exists mainly in the form of a 
monomer with a charge state distribution ranging from +9 to +7, accompanied by a lower 
abundance by the form of dimer with a charge state distribution ranging from +13 to +11 
(Figure 1). This self-association of FGF1 has been reported before [51, 64], but the 
biological relevance of the self-association that we observed is not clear because of its low 
abundance. The narrow distribution of lower charge states indicates that FGF1 ions adapt a 
folded and compact conformation with fewer basic sites exposed for protonation [65]. Each 
observed charge state displays three peaks, corresponding to the sequence mass of FGF1 and 
masses corresponding to variants with one less amino acid from either the N-terminus or C-
terminus. Owing to the compositional complexity, only the peaks of lowest mass were 
selected for further ion mobility analysis.
In an effort to examine the binding stoichiometry for the interaction of FGF1 and HS, a 
series of tetrasaccharides (dp4) with different sulfation patterns were incubated with FGF1 
in a molar ratio of 1:2. The HS dp4a contains the high affinity binding motif for FGF1 
IdoA2S-α-(1-4)-GlcNS6S-α-(1-4)-IdoA2S [24]. HS dp4b has the same overall level of 
sulfation as the dp4a, but the 2-O sulfation on the first residue from the nonreducing end was 
shifted to 3-O sulfation on the second residue, accompanied by the change of uronic acid 
stereochemistry (GlcA instead of IdoA) at the non-educing end. The HS dp4c lacks two 2-O 
sulfo groups compared with dp4-1. In the presence of HS, the formation of the 1:1 FGF1–
HS complex was observed (Figure 1) without altering the charge state distributions of apo-
FGF1. It is noteworthy that two peaks corresponding to a complex of two FGF1s with one 
HS (2:1 FGF1–HS complex) were detected only for the HS dp4a containing the high affinity 
binding motif (Figure 1d).
A majority of previous studies suggest that dimerization of FGF1 or complexation of FGF1 
with HS and FGFR requires a long-chain HS oligosaccharides (at least a hexasaccharide or 
octasaccharide) [23, 66]. Other studies showed that a fully sulfated dp4 is sufficient for a 
high-affinity interaction with FGF [67, 68], for stabilizing FGF1 against thermal unfolding 
or digestion [69], and for initiating mitogenic activity [70]. A dimeric complex of FGF1 and 
HS as well as trimeric complex of HS, FGF1, and FGFR1 produced in the presence of 
tetrasaccharides containing the critical binding motif have been detected using MALDI mass 
spectrometry [71] and gel mobility shift assay [68]. Our observations highlight the 
importance of this critical binding motif, which imparts upon HS oligosaccharides as short 
as a tetrasaccharide the potential to induce FGF1 dimerization.
The arrival time distributions of the +7 charge state of FGF1 alone, the +7 charge state of 1:1 
FGF1–HS dp4a complex, and the +12 charge state of 2:1 FGF1–HS dp4a complex are 
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shown in Figure 2a, recorded at a wave height of 17 V. One narrow arrival time distribution 
was observed for each species, indicating the presence of one compact and folded 
conformation for the protein ion and the noncovalently associated protein– HS assemblies at 
both binding stoichiometries. These observations suggest that the solution structure of FGF1 
survived in the gas phase environment of TWIMS, maintaining its capability to bind to HS.
The peak corresponding to the even charge state of the 1:1 FGF1–HS complex overlaps in 
the mass spectrum with that corresponding to the 2:2 FGF1-HS complex with a doubled 
charge. However, the dimeric complex has a decreased charge-normalized cross section [72] 
so that it can be separated from the monomeric complex on the basis of a difference in drift 
times in a TWIMS experiment (Figure 2b). The feature with the longer drift time 
corresponds to the 1:1 FGF1–HS dp4 complexes, each of which exhibits a narrow drift time 
distribution as observed for the same species in a different charge state (Figure 2a). The 
features with shorter drift times correspond to 2:2 FGF1–HS complexes. One narrow arrival 
time distribution was detected for the FGF1–HS dp4a mixture, implying the presence of a 
single compact, ordered gas-phase conformation, in strong contrast to the broader peak with 
many features detected for the FGF1–HS dp4b mixture or the FGF1–HS dp4c mixture, 
implying the existence of a range of less specific binding modes.
The fact that subtle alterations of the HS sequence with regard to the sulfation pattern or 
epimerization lead to noticeable changes in both the binding stoichiometry and the binding 
mode of the FGF1–HS interaction suggest that the interactions between FGF1 and HS has 
certain degree of selectivity. These observations strengthen the importance of the critical 
binding motif in modulating the assembly of FGF1 and HS through a specific dimerization 
mode.
IMMS of HS Dodecasaccharide Bound FGF1 Complexes
A series of dodecasaccharides (dp12) with varying sulfation patterns were incubated with 
FGF1 at a molar ratio of 1:4 (GAG to protein) (Figure 3). An excess of FGF1was used to 
saturate the FGF1 binding epitopes on the dp12s. In the presence of the fully sulfated HS 
dp12, the binding of one HS dp12 to three FGF1 (3:1 FGF1–HS complex) were detected 
with a charge state distribution ranging from +15 to +13, accompanied by the binding of one 
HS dp12 to two FGF1 (2:1 FGF1–HS complex) with a charge state distribution ranging from 
+13 to +11. Peaks corresponding to apo-FGF1 were also detected, but in very low 
abundance compared with that for the complexes. Previous studies showed that the 
interaction between FGF1 and HS is driven by positive cooperativity [34, 73], so that FGF1 
oligomerizes in preference to staying in monomeric state when bound with long-chain HS, 
and the formation of higher order of FGF1 oligomers was observed as the length of HS 
increases [74]. Our observations are consistent with these previous studies and highlight the 
biological function of HS as a storage reservoir for FGFs on the cell surface [23].
The presence of de-2-O sulfated or de-6-O sulfated dp12 also resulted in two types of 
binding stereochemistry to FGF1, but their abundance was much lower than that of the fully 
sulfated dp12 for FGF1. In the presence of de-2-O and 6-O sulfated dp12, only a small 
fraction of FGF1 formed 2:1 FGF1–HS complex, whereas mostof FGF1 stayed inapo form. 
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The marked difference in binding stoichiometry implies that the absence of 2-O and 6-O 
sulfo groups dramatically reduces the binding affinity.
Although the modified dp12s exhibit varying binding stoichiometry to FGF1, the arrival 
time distribution of the 3:1 FGF1–HS dp12 complexes all exhibited a single, narrow peak. 
The same observation has been reported for a different GAG– protein binding system, 
chemokine CCL2 and HS [75]. The fact that the ion mobility profiles of FGF1-modified HS 
dp12 complexes are similar implies that changes in HS structure lead to altered interactions 
with FGFs, but these alterations may not dramatically affect the compact, gas-phase 
conformation adapted by these complexes.
Our observations suggest that long-chain HS may not place as stringent requirement on the 
fine structure of HS sequence as short-chain HS, indicating a relative lack of specificity of 
binding for long-chain HS. Instead of presenting a specific binding motif for FGF1, the 
sequence of HS may be composed of many domains with different sulfation patterns and 
binding affinities toward FGF1, forming an affinity gradient on the cell surface that regulates 
FGFs signaling by directing them to the site of interaction [76].
CCSs of FGF1-HS Complexes
A comparison of the experimental and theoretical CCSs for the HS bound FGF1 complexes 
were carried out to determine their binding mode as well as the higher order oligomerization 
behavior of FGF1. The experimental CCSs for the complexes (Table 1) were calibrated 
based on an empirical relationship between the drift times of protein calibrants and their 
known CCSs obtained previously by conventional drift time IMS. For theoretical estimation, 
we used both the projection approximation (PA) [77] and the trajectory (TM) [63] method. 
PA estimates the orientationally-averaged CCS by projecting the molecule onto a randomly 
chosen plane in space, drawing a circle with the corresponding collision radius around the 
projection of each atom, and estimating the area of the “shadow” from all faces [78]. This 
method is known to underestimate CCS since it fails to consider the influence of long-range 
interactions and the scattering between the ion and neutral gas. TM represent the ions as a 
collection of atoms defined by their Lennard-Jones (12-6-4) potential, and relates the 
scattering angle of the buffer gas molecules before and after collision with the molecule's 
geometry. An orientationally-averaged CCS can be obtained by integrating over all possible 
collision geometries of the ion; however, this method is computationally much more 
intensive than the PA method [63]. The experimental CCSs are generally found to be larger 
than those computed using the PA method, and smaller than the TM results [79]. A previous 
study [80] have shown that there is a direct scaling relationship between experimental CCS 
and values calculated using PA methods, so calibrating the PA CCSs though this scaling 
relationship should provide a good standard for correct interpretation of experimental data.
Each model of the 2:1 FGF1–HS complex (Figure 4a) was based on the crystal structure 
2AXM, which contains a heparin hexasaccharide bound to two molecules of FGF1 in trans 
orientation. The FGF1–dp4 complex was built by removing two residues from the 
hexasaccharide. For the complexes formed with oligosaccharides with chain length longer 
than dp6, we extended the crystal hexasaccharide sequence to build models for dp8 and 
higher in a relatively straightforward manner. However, considering the fact that changing 
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the interactions at the binding interface between the two FGF1 molecules to accommodate 
GlcA in place of IdoA would affect the interaction dramatically, we chose to use the crystal 
structure for the FGF1–dp6 modeling.
Molecular dynamics (MD) simulations of these complexes were carried out in explicit 
solvent, followed by in vacuo minimization of a subset of the frames from the MD 
trajectories and CCS calculations. The theoretical CCSs for the FGF–dp6 complex do not 
follow the same trends as the other complexes, and the PA and TM numbers offer a slightly 
larger range due to the difference between the experimental and theoretically modeled dp6. 
A comparison of the experimental and theoretical CCSs for the five complexes shows that 
the experimental numbers lie between the PA and TM numbers, as expected. The 
experimental CCSs are on an average 12% lower than the TM numbers, which is as expected 
because of the partial collapse of the protein structure as a result of desolvation [81, 82]. The 
experimental CCSs are on an average 13% higher than the PA numbers, which is in 
agreement with previous studies [40, 83], which report experimental CCS to be about 15% 
higher than PA estimates. We have also reported the scaled PA numbers, which showed a 
close agreement with the experimental numbers. Moreover, we have compared the 
representative structure of the dimeric protein complex during the MD simulation and after 
the in vacuo minimization (as shown in Supplementary Data, Figure 6). The protein 
backbones RMSD between the two structures is 2.07Å, suggesting that there is no dramatic 
change of the overall shape of the protein, and the most relevant features of the protein 
structure are still retained. These results imply that the desolvation process in the TWIMS 
experiment did not significantly alter the solvated structure of FGF1 and its complexes, and 
their biological function to bind with HS was still retained.
In terms of the gas-phase stability of these complexes, it is noteworthy that the 
experimentally derived CCSs for the five complexes formed with HS of varying lengths lie 
very close to each other, with the difference between FGF1–dp4 and FGF1– dp12 being 100 
Å2. This difference in the CCSs appears to arise only due to the size of the HS fragment, 
implying that the compact and folded conformations of the FGF1 complexes were not 
disturbed and remained stable during the TWIMS experiments.
A comparison of the CCS of the protein from the crystal structure (PDB id: 2AFG) and the 
protein after removal of the HS tetrasaccharide from the 1:1 FGF1–dp4 complex was made 
to determine any conformational changes induced in the protein upon HS binding. The 
conformational difference in the CCS of the two protein-forms was calculated to be less than 
1% using both the TM and PA methods (data in Supplementary Table 2). We can therefore 
conclude that there is no major conformational change brought about in the protein as a 
result of HS binding, and the overall increase in the CCS can be attributed to the presence of 
HS itself, which is in agreement with previous studies [76, 84].
Two different dimerization modes for FGF2 have been previously proposed [17]. In the 
presence of long-chain HS fragments, FGF2 molecules oligomerize to form side-by-side cis 
dimers, whereas with short-chain HS disaccharides they form head-to-head trans dimers 
[17]. Similar observations have not been made for FGF1, and the crystal structures available 
in the PDB for 2:1 FGF1–HS complex only indicate a trans binding mode. We generated 
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two models for the plausible cis forms of 2:1 FGF1–HS dp12 complexes (Supplementary 
Figure 1). Cis-model-1 used two FGF1–dp6 molecules joined through the GAG chain, with 
a cis-like starting conformation, to examine whether formation of cis form for FGF1 may be 
feasible, and if it could be differentiated from the trans model on the basis of differences in 
the CCS. However, during the course of MD simulations, it adopted a more trans-like 
conformation, likely due to the lack of stable protein–protein interactions between the two 
FGF1 molecules. In contrast, the Cis-model-2, based on the crystal structure of apo-FGF1 
dimer (PDB id: 2AFG) with stable protein–protein interactions, was able to maintain the cis 
conformation during MD simulations. The models differed significantly in their starting and 
end conformations; however, both formed compact structures that lead to very similar 
theoretical CCS (data in Supplementary Table 3), making them indistinguishable from each 
other, and also from the trans form (Table 1). On the basis of this data, therefore, it is 
difficult to determine whether the cis form exists in solution, but if it does, it may be difficult 
to distinguish the cis and the trans binding conformations solely based on the CCS.
The TWIMS experiments also detected a 3:1 FGF1–HS complex in the presence of select 
sulfated HS–dp12. A plausible model, with three molecules of FGF1 in contact with HS– 
dp12, was computationally examined, using a model that melds the available crystal 
structure for 2:1 FGF1–dp6 dimeric complex (Figure 4b) with a 1:1 FGF1–dp6 monomeric 
complex through the HS chain. For this study, it was ensured that each of the three FGF1 
molecules interacts directly with the HS since the formation of this higher order oligomer 
seems to be induced only in the presence of HS. The MD simulation of the complex was 
followed by calculation of CCS, and the experimentally calculated CCS was found to lie 
between the theoretically obtained CCS, using the PA and TM methods. Specifically, the 
experimental number was 15.9% higher than the PA and 11% lower than the TM methods. 
Although this is only one of the plausible 3:1 FGF1–HS models, the agreement with 
experimental CCS values provides reasonable confidence in believing that a 3:1 complex 
would adopt a similar oligomeric conformation.
Gas-Phase Stability of FGF1 and Its Complexes
The impact of GAG binding upon the stability of the three-dimensional structure of FGF1 
was examined using collision induced unfolding (CIU) experiments, an approach developed 
by Ruotolo and co-workers [47]. We performed a series of collision-induced activation 
experiments with incremental changes in trapping collisional energy (CE) applied to 
selected protein and protein complex ions. Their conformational transition from a fully 
folded to a fully unfolded state was tracked, and was used to assess the ligand-induced 
influence on the gas-phase stability of these ions. A range of HS oligosaccharides of 
increasing lengths, containing the critical binding motif of IdoA2S-α-(1-4)-GlcNS6S-α-
(1-4)-IdoA2S, were used to form dimeric and monomeric complexes with FGF1. The +8 
charge state of monomeric protein complex ions was selected for activation, since this 
charge state provides higher ion intensity, sufficiently stability against low-energy 
dissociation, and distinguishable unfolding features within a relatively narrow collision 
energy window. The resulting CIU fingerprints of FGF1 and FGF1–HS complexes are 
shown in Figure 5, which record the drift time and intensity of each conformation feature 
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that emerged during the unfolding process as the trap CE was ramped from 0 to 60 V in a 
2.5 V increment.
The CIU fingerprint of unbound, apo-FGF1 exhibits three features. The first feature, which 
has the lowest drift time at 7.9 ms, corresponded to the most compact conformation of the 
protein ion. As the CE was raised to 10 V, this compact conformation diminished while the 
second feature appeared at 10.2 ms, corresponding to the intermediate state with a more 
extended conformation. Beyond the CE of 12.5 V, the third feature started to emerge and 
stabilized at 14.3 ms, indicating that the three-dimensional protein structure had unfolded 
completely.
The CIU fingerprints of 1:1 FGF1–HSdp4/HSdp6 complexes showed similar unfolding 
pathways as the apo-FGF1, for which the most extended conformation was dominant across 
the investigated voltage range. However, for both complexes, not only their most compact 
feature but also their partially unfolded feature showed a more elongated shape than those 
for the apo-FGF1. An increase of 2.5 V in the voltage at which the most compact feature 
starts to unfold was observed. A similar trend was observed for the voltage at which the 
intermediate feature further extends, shifting the voltages by 5 and 10 V, for the dp4-bound 
FGF1 and dp6-bound FGF1, respectively.
The CIU fingerprints of 1:1 FGF1–HSdp8 and –HSdp10 complexes show an even more 
substantial elevation of the voltage at which the most compact feature starts to unfold, 
shifting the voltage by 5 and 10 V, respectively. More importantly, the intermediate 
conformation gained more stability and became dominant for over 66.7% of the investigated 
voltage range. It is notable that the intermediate state and the extended state stabilize 
simultaneously for a longer voltage range, indicating that they have a different unfolding 
pathway from the species discussed above.
In significant contrast to the 1:1 short-chain HS complex bound FGF1 complex, the CIU 
fingerprint of the 1:1 FGF1–HSdp12 complex exhibited only two principal conformational 
features, corresponding to the fully folded conformation at 8.7 ms and the intermediate 
conformation at 11.7 ms, respectively. The survival of the relatively compact conformations 
at high voltages and the absence of the most extended conformation clearly suggest an even 
higher resistance towards collision induced unfolding than the apo-FGF1 or short HS bound 
FGF1 complexes.
The effect of collisional activation was also measured for 2:1 FGF1–HS complexes with HS 
oligosaccharides of different lengths, and a similar trend as the 1:1 FGF1–HS complexes 
was observed (Supplementary Figure 2). Comparing the fingerprints clearly shows a 
significant enhancement of the gas-phase stability of FGF1 upon the binding of HS 
oligosaccharides, regardless of the stoichiometry of the complexes formed. These 
observations are consistent with the solution-phase behavior of the FGF1 signaling system, 
which show that HS improves the conformational stability of FGF–FGFR complex against 
thermal, enzymatic, or pH-dependent inactivation and degradation [85, 86].
CIU fingerprints of the +12 charge state of the 2:1 FGF1-selected sulfated HS dp12s were 
also compared (Supplementary Figure 3). At low collision energy, their ion mobility profiles 
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all exhibited single, narrow-distribution peaks, indicating that they exist in their compact 
conformation in the gas phase. As the trap CE was ramped from 0 to 40 V, the 2:1 FGF1–
fully sulfated dp12 complex showed a slightly higher stability. Nevertheless, all four 
complexes exhibited similar behavior in their unfolding mode, with one compact and one 
unfolded state with similar centroid drift times and stability ranges. These observations 
indicate that length of the HS oligomer may be more important than its sulfation pattern in 
determining the gas-phase stability of these protein complexes.
Previous studies proposed that the stability of FGF complexes depends more on the overall 
degree of sulfation rather than a specific arrangement of the sulfation groups [25]. Our 
observations suggest a more complicated mechanism than that: four selectively sulfated 
dp12s display similar conformational stability and gas-phase unfolding behavior despite 
their different overall extent of sulfation; The de 2-O and 6-O sulfated dp12 with only six 
sulfo groups have a much higher gas-phase stability than the fully sulfated dp4 to dp8 
(which have six or more sulfo groups). Apparently, both the length of the HS 
oligosaccharide and the distribution of sulfo groups contribute to stabilizing the gas-phase 
conformation of HS-bound FGF1 complexes.
Since the most compact feature should resemble the native structure of a protein complex, 
the CE required for its transition to a more extended state should be an experimentally 
quantitative estimation of the binding affinity of the HS oligosaccharide towards FGF1 [87]. 
Thus, we measured and plotted the voltage at which the most compact feature starts to 
unfold for each HS-bound FGF1 complex, as shown in Figure 6. The degree of stabilization 
is observed to correlate with the length of the HS oligosaccharide, with long-chain HS 
oligosaccharides interacting with FGF1 and forming complexes that slowed down the 
initiation and the process of collision-induced unfolding more effectively than short-chain 
HS.
Theoretically, the stability of a complex can be measured as the strength of interaction 
between the binding partners, and it would be reasonable to believe that the greater the 
binding affinity, the higher will be the stability, and consequently a higher CE would be 
required to induce unfolding of the complex. Binding free energies of FGF1 in complex with 
HS of increasing lengths (dp4–dp12), in both 1:1 and 2:1 binding stoichiometry (Figure 4a) 
were calculated to provide theoretical quantification. In vacuo minimization of a subset of 
the frames from the MD trajectories was carried out, followed by energetic post-processing 
to obtain the gas-phase interaction energies to mimic the binding modes representative of 
these complexes during mass spectrometry experiments. We observed that the interaction 
energies for the monomeric and dimeric complexes both increase as the length of the HS 
chain increases (Figure 6), as expected. These results are in direct agreement with the 
observed experimental stability trends of the FGF1-HS complexes.
The increase in the stability of the complex with an increase in the length of the HS chain 
can be attributed to the additional number of saccharide residues which present more sulfo 
and carboxyl groups to interact with the protein [73]. It was also observed during the MD 
simulations that the longer HS chains fold onto the proteins, forming more interactions with 
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proteins, further restraining the shape of these structures, and providing them with more 
resistance to collision-induced unfolding.
These observations demonstrate that while a HS oligosaccharide as short as a tetramer is 
capable of promoting the formation of a FGF1 dimer complex (2:1 protein:tetramer 
stoichiometry), its stability is generally low due to its low efficiency to counteract the charge 
repulsion between the two protein surfaces [18, 19]. This is consistent with the observation 
that lower concentrations of long-chain HS oligosaccharides display tighter binding and 
higher biological activity, whereas HS dp4 support FGF signaling only when present at a 
high concentration [67].
Conclusions
Although previous studies of FGF1–FGFR2–HS complexes have reported using mass 
spectrometry, relying upon size-exclusion chromatography to determine the dominant 
configuration of the ternary complex [88], less structural information was extracted about 
the influence of the variation of HS chain length and sulfation pattern on the FGF1–HS 
interactions. In the present work, we have applied IMMS to the FGF1–HS signaling 
complexes and used molecular modeling to interpret the results. This approach has led to a 
number of important new conclusions. Although some previous results suggest that HS 
octasaccharide is the minimal length required for FGF1 dimerization and activation, our 
results showed that a short tetrasaccharide containing the high affinity binding motif is 
capable of dimerizing FGF1, forming complexes with a compact, well-defined gas-phase 
conformation. These finding demonstrate the importance of high-affinity binding motif for 
promoting the correct assembly of FGF1, as well as dictating the binding selectivity of 
FGF1–HS binding. Moreover, we found that FGF1 can participate in high order oligomers 
when interacting with long-chain HSs (dodecasaccharides), and the degree of 
oligomerization increases as the chain length of HS increases. However, the ion mobility 
profiles of FGF1 in complex with dodecasaccharides with different patterns of sulfate 
modification did not show much difference in stability, indicating a relative lack of 
specificity of binding with long-chain HS.
Furthermore, the experiments of collisional activation of FGF1 and FGF1–HS complexes 
confirmed the stabilizing effect of HS binding on the folded structure of FGF1. The degree 
of stabilization correlates with the length of the HS oligosaccharide, with longer HS 
oligosaccharides forming a complex that has higher gas-phase stability against collision-
induced unfolding. The stability of the FGF1–HS complexes correlate with the overall 
degree of sulfation rather than on the precise location of sulfo groups. Finally, collisional 
cross-sections of FGF1–HS complexes have been examined using theoretical models built 
using the available X-ray crystal structures of FGF1 in complex with HS. MD simulations 
with these models are in agreement with the experimental results, indicating that the folded 
gas-phase conformation of FGF1 and its binding activity survive the transition of the ions 
into the gas phase. We also proposed a plausible structure for the 3:1 FGF1–HS complex. 
The binding affinity of HS of varying lengths has also been studied using molecular 
modeling, which gave results consistent with experiments.
Zhao et al. Page 15
J Am Soc Mass Spectrom. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Collectively, these results extended the application of TWIMS for investigating GAG–
protein interactions at the molecular level. Characterization of the interactions between 
FGF1 and HS will benefit the understanding of the full magnitude FGF signaling pathways 
and, eventually, the development of new medicines. The extension of the methodology will 
add further dimensions to the drug-development studies of a large array of other GAG-
binding proteins.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
ESI mass spectra, obtained under nondenaturing conditions, of (a) FGF1 itself; (b) FGF1 
incubated with HS dp4c at 2:1 ratio; (c) FGF1 incubated with HS dp4b at 2:1 ratio; (d) 
FGF1 incubated with HS dp4a at 2:1 ratio. Associating of two FGF1s by one HS (2:1 
FGF1–HS complex) were observed only for the HS dp4a containing the high affinity 
binding motif
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Figure 2. 
(a) Arrival time distributions (ms) of +7 charge state of FGF1 (upper), +7 charge state of 1:1 
FGF1–HS dp4a complex (middle) and +12 charge state of 2:1 FGF1–HS dp4a complex 
(lower). The narrow arrival time distribution observed for each species indicates that the 
native structure of FGF1 and the noncovalent complex of FGF1 with HS are stable in the 
TWIMS experiment. (b) Arrival time distributions (ms) of +6 charge state of 1:1 FGF1–HS 
complex and +12 charge state of 2:2 FGF1–HS complex, with HS4a (upper), HS4b 
(middle), and HS4c (lower). The comparison between the narrow, well-defined arrival 
distribution of 2:1 FGF1–HS dp4a complex and the broad arrival time distribution of 2:1 
FGF1–HS dp4b complex or 2:1 FGF1–HS dp4c complex indicates that the high affinity 
binding motif is responsible for the level of specificity in the dimerization of FGF1 upon the 
binding of HS
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Figure 3. 
Native ESI mass spectra of (a) FGF1 with de-2-O- and de-6-O-sulfated dp12; (b) FGF1 with 
de-2-O-sulfated dp12; (c) FGF1 with de-6-O-sulfated dp12; (d) FGF1 with the dp12 that 
contains the critical binding motif. Structures of the dp12s are shown in Supplementary Data
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Figure 4. 
(a) Structural representation of 2:1 FGF1–HS complexes, displaying the binding of dp4-
dp12 (left to right). The protein and HS are shown in ribbon and stick representation, 
respectively. (b) Structural representation of the hypothesized 3:1 FGF1–HS 
dodecasaccharide complex, obtained by connecting the available crystal structure for 2:1 
FGF1–dp6 dimeric complex with a 1:1 FGF1–dp6 monomeric complex through the HS 
chain
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Figure 5. 
The 2D-contour CIU fingerprint of the monomeric apo-FGF1 and the 1:1 FGF1-HS, with 
HS of increasing length from dp4-dp12. The conformations were labeled as F, I, and U, 
indicating folded, intermediate, and unfolded states, respectively. The ion intensities are 
indicated by a color axis. As the length of the HS increases, they form complexes with FGF1 
and increase the conformational stability of the complexes accordingly
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Figure 6. 
Trends for the experimental transitional voltages required for inducing unfolding for the 
stability of the FGF1–HS complexes in the 1:1 (a) and 2:1 (c) binding stoichiometry 
compared with the trends for theoretical binding free energies for the 1:1 (b) and 2:1 (d) 
complexes. The two trends are comparable, indicating that the binding of longer heparin 
oligosaccharides imparts greater stability to the protein against unfolding
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